The non-clinical safety evaluation platform offers internationally recognized safety solutions to support drug development with advanced experimental animal technologies, diverse species resources, and regulatory expertise. It specializes in evaluating toxicity biomarkers, genotoxicity, addiction potential, ophthalmic safety, and cardiotoxicity, playing a crucial role in assessing the safety of cutting-edge drugs, including novel small molecules, biologics, bispecific/multispecific antibodies, ADCs, nanobodies, peptides, nucleic acid therapies, and cell/gene therapies (immune/stem cells, oncolytic viruses, AAV vectors).
InnoStar’s platform provides precision and compliance in safety assessments, accelerating the development of complex therapeutics through integrated in vitro/in vivo models and tailored safety strategies. The focus is on aligning technical excellence with global regulatory standards, ensuring rapid and safe translation from preclinical studies to clinical trials, and establishing trust among biopharma innovators worldwide.